The startup develops small molecule anti-cancer drugs using technologies such as the LINTMED evaluation for innate immune responses and the BaF3 system for kinase inhibitors. This approach targets RAS mutations and enhances immunotherapy, providing patients with more effective treatment options for cancer-related diseases.
Funding
$17.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer treatments face challenges in effectively targeting RAS mutations, a common driver of tumor growth, and in fully leveraging the body's innate immune system to fight cancer cells. Current therapeutic options may have limited efficacy or fail to provide durable responses for patients with RAS-driven cancers.
Solution
This startup is developing small molecule anti-cancer drugs designed to specifically target RAS mutations and enhance innate immune responses against tumors. Their approach utilizes the LINTMED evaluation technology to assess and optimize innate immune responses, and the BaF3 system for the development of potent kinase inhibitors. By combining these technologies, the company aims to create more effective and targeted therapies that improve patient outcomes in cancer treatment. The focus is on providing innovative treatment options that address the limitations of existing therapies and offer new hope for patients and their families.
Target Audience
The primary target audience includes cancer patients, their families, and oncologists seeking more effective and innovative treatment options for RAS-driven cancers.
Features
- Small molecule drug development targeting RAS mutations.
- LINTMED evaluation technology for assessing innate immune responses.
- BaF3 system for kinase inhibitor development.
- Focus on enhancing immunotherapy efficacy.
- Development of targeted therapies for cancer-related diseases.